Company Overview and News

19
U.S. IPO Week Ahead: The Calm Before The Fall

2018-09-01 seekingalpha
While there are no IPOs scheduled to price in the shortened holiday week, this summer has been the busiest since 2014, and we expect that rate to continue post-Labor Day. 77 US IPOs are publicly on file as of August 30, including 45 that have kept their filings current. We estimate that 70-90 more US IPOs could raise over $20 billion by year-end. Stay tuned for our Fall Preview coming out Tuesday with more estimates.
PCB MSRPW MESA IPO AMAL SPOT ATH VCNX IPOS PFCF

8
Mesa Air Group: Not Flying High

2018-08-13 seekingalpha
I understand why investors are cautious given the high debt, modest earnings power and troubled past.
MSRPW MESA AAL UAL

 
IPO News This Week: As August Heats Up, Offerings Cool Off

2018-08-12 247wallst
Last week’s initial public offering (IPO) action saw four of five scheduled listings make their entry into the public markets. The four IPOs raised a total of $307 million in new capital, as three of the four priced below the midpoint of their expected ranges. The coming week includes two small offerings seeking a total of $58 million, one a first-timer and one a holdover from last week.
SPAQ PCB BNGO MSRPW MESA VCNX AMAL PFCF

1
U.S. IPO Weekly Recap: 4 Small IPOs Price Ahead Of August Doldrums

2018-08-11 seekingalpha
The IPO market's very active summer 2018 has wrapped up. This week, four small IPOs got in before the annual August pause. Each priced below the midpoint to raise a combined $307 million. A regional airline, two regional banks, and biotech averaged a 0% return. Top performer Amalgamated Bank (AMAL) finished with a mere 6% gain, and the other three were negative. Trading was poor, but that came as no surprise to our institutional research clients (the deals didn't screen out particularly well on IPO Pro's MUSCLE Method, either).
SPAQ PCB MSRPW MESA AMAL VCNX APO PFCF

10
Mesa Air Returns to Market With Downsized $116 Million IPO - Bloomberg

2018-08-10 bloomberg - 2
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
MSRPW AAL RJD UAL RJF

 
MSRPW / Mesa Air Group, Inc. null

2018-08-09 sec.gov
begin 644 8A_Cert_MESA.pdf M)5!$1BTQ+C4-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V5S+T-O=6YT(#$O2VED%[email protected]," P(#8Q,BXQ,B W.3(N,3)=("]# M;VYT96YT
MSRPW

 
MSRPW / Mesa Air Group, Inc. FORM 8-A12B

2018-08-09 sec.gov
Form 8-A12B As filed with the Securities and Exchange Commission on August 9, 2018
MSRPW

2
Mesa Air Group IPO: Take To The Skies With This Regional Airline

2018-08-09 seekingalpha
For the first time in years, an airline which offers shares to the public in an initial price offering. Beginning this week, regional airline Mesa Air Group (MESA) will be publicly traded. Less than eight years after emerging from bankruptcy, the parent company of Mesa Airlines has presented a strong case on why they deserve forgiveness and your investment.
MSRPW SKYW DAL

 
MSRPW / Mesa Air Group, Inc. FWP

2018-08-08 sec.gov
FWP Issuer Free Writing Prospectus dated August 8, 2018 Filed Pursuant to Rule 433 under the Securities Act of 1933 Relating to Preliminary Prospectus dated July 30, 2018 Registration
MSRPW

 
MSRPW / Mesa Air Group, Inc. S-1/A

2018-08-08 sec.gov
S-1/A Table of Contents As filed with the Securities and Exchange Commission on August 8, 2018 Registration No. 333-226173
MSRPW

 
MSRPW / Mesa Air Group, Inc. S-1/A

2018-08-06 sec.gov
S-1/A As filed with the Securities and Exchange Commission on August 6, 2018 Registration No. 333-226173
MSRPW

1
IPO News This Week: Regional Airlines, 2 Banks Head New Offerings

2018-08-06 247wallst
Last week’s initial public offering (IPO) action saw 5 scheduled listings make their entry into the public markets. The 5 IPOs raised a total of $1.38 billion in new capital. The month of July ended with 33 completed IPOs and August kicks off with 5 more seeking nearly $400 million in capital.
SONO SONOS BNGO MSRPW CVON CWK FMCI TOTAU ARLO FMCIU PFCF

27
U.S. IPO Week Ahead: 5 IPOs Feature Regional Banks And A Regional Airline

2018-08-04 seekingalpha
A handful of small IPOs are set to price before the August break, with five raising less than $400 million.
MSRPW AMAL SPOT AAL ATH UAL PFCF

 
Mesa Air Group Readies Plan For $161 Million IPO

2018-08-01 seekingalpha
The firm is growing topline revenues, but at a decelerating rate; financial results have been uneven.
MSRPW

1
Mesa Air Announces Potential Pricing for IPO

2018-07-30 247wallst - 1
Mesa Air Group has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company expects to price its 10.7 million shares in the range of $14 to $16, with an overallotment option for an additional 666,667 shares. At the maximum price, the entire offering is valued up to $184.58 million. The company intends to list on the Nasdaq under the symbol MESA.
MSRPW

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 590479101